TherapeuticsMD, Inc. Begins Phase 3 Clinical Trial Of TX-004HR (VagiCapTM) For The Treatment Of Painful Intercourse, A Symptom Of VVA, Due To Menopause

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD Inc. (NYSE MKT: TXMD), an innovative women’s healthcare company, announced today that enrollment opened for its Rejoice Trial, a phase 3 clinical trial of TX-004HR (VagiCapTM) to evaluate multiple doses of an investigational, applicator-free estradiol for treatment of painful intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.

Help employers find you! Check out all the jobs and post your resume.